Chen Xuyang, Ma Zeliang, Ren Yinghong, Che Ya, Chen Genxiang, Liu Qian, Zhao Xinhan
Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Department of Oncology, Shangluo Central Hospital, Shangluo, Shaanxi Province, China.
Medicine (Baltimore). 2025 Jul 25;104(30):e43367. doi: 10.1097/MD.0000000000043367.
The role of postoperative radiotherapy (PORT) for non-small cell lung cancer (NSCLC) is still debated. A nonlinear relationship may exist between the number of positive lymph nodes (PLN) and the benefits of PORT. Our study seeks to identify patient subgroups that could benefit from PORT by stratifying them based on PLN counts. We enrolled patients with pathologic N2 NSCLC who underwent surgery and adjuvant chemotherapy between January 2004 and December 2015 from the surveillance, epidemiology, and end results (SEER) database. Overall survival (OS) and lung cancer-specific survival (LCSS) were compared between patients receiving PORT and those not receiving PORT. The restricted cubic spline analysis model was applied to investigate the relationship between PLNs and survival. The Kaplan-Meier method was used to generate survival curves, and the log-rank test was applied to compare survival outcomes between the PORT and non-PORT groups. Cox proportional hazard models were employed to calculate adjusted hazard ratios and their corresponding 95% confidence intervals. A total of 4048 patients were eligible, with a median follow-up time of 103 months. PORT had a negative impact on OS (HR = 1.08, 95% CI = 1.01-1.17, P = .03) and showed no association with LCSS (HR = 1.06, 95% CI = 0.98-1.15, P = .14). The restricted cubic spline analysis analysis indicated that PLN counts could modify the effects of PORT on survival. Patients were categorized into 3 risk subgroups according to their PLN counts: low-risk (1-4 PLNs), moderate-risk (5-6 PLNs), and high-risk (over 6 PLNs). In the low-risk subgroup, PORT exhibited an adverse effect on OS (HR = 1.17, 95% CI = 1.00-1.28, P < .01). Conversely, in the moderate-risk subgroup, PORT improved OS (HR = 0.72, 95% CI = 0.60-0.87, P < .01). In the high-risk subgroup, PORT had no impact on OS (HR = 1.00, 95% CI = 0.86-1.16, P = 1.00). Analysis in LCSS showed consistent results. While PORT does not universally improve survival outcomes for all patients with pN2 NSCLC, it improves survival for those with a moderate number of PLNs.
术后放疗(PORT)在非小细胞肺癌(NSCLC)中的作用仍存在争议。阳性淋巴结数量(PLN)与PORT的获益之间可能存在非线性关系。我们的研究旨在通过根据PLN计数对患者进行分层,确定可能从PORT中获益的患者亚组。我们从监测、流行病学和最终结果(SEER)数据库中纳入了2004年1月至2015年12月期间接受手术和辅助化疗的病理N2期NSCLC患者。比较了接受PORT和未接受PORT的患者的总生存期(OS)和肺癌特异性生存期(LCSS)。应用受限立方样条分析模型研究PLN与生存期之间的关系。采用Kaplan-Meier方法生成生存曲线,并应用对数秩检验比较PORT组和非PORT组的生存结果。采用Cox比例风险模型计算调整后的风险比及其相应的95%置信区间。共有4048例患者符合条件,中位随访时间为103个月。PORT对OS有负面影响(HR = 1.08,95%CI = 1.01 - 1.17,P = 0.03),且与LCSS无关(HR = 1.06,95%CI = 0.98 - 1.15,P = 0.14)。受限立方样条分析表明,PLN计数可改变PORT对生存的影响。根据PLN计数将患者分为3个风险亚组:低风险(1 - 4个PLN)、中度风险(5 - 6个PLN)和高风险(超过6个PLN)。在低风险亚组中,PORT对OS有不良影响(HR = 1.17,95%CI = 1.00 - 1.28,P < 0.01)。相反,在中度风险亚组中,PORT改善了OS(HR = 0.72,95%CI = 0.60 - 0.87,P < 0.01)。在高风险亚组中,PORT对OS无影响(HR = 1.00,95%CI = 0.86 - 1.16,P = 1.00)。LCSS分析显示了一致的结果。虽然PORT并非对所有pN2期NSCLC患者的生存结局都有普遍改善作用,但它能改善那些PLN数量适中的患者的生存。